StockNews.com initiated coverage on shares of FibroGen (NASDAQ:FGEN – Free Report) in a research note published on Wednesday morning. The firm issued a hold rating on the biopharmaceutical company’s stock.
Separately, William Blair reaffirmed a market perform rating on shares of FibroGen in a research report on Monday, June 3rd.
View Our Latest Research Report on FGEN
FibroGen Stock Up 11.0 %
FibroGen (NASDAQ:FGEN – Get Free Report) last issued its quarterly earnings data on Tuesday, August 6th. The biopharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.25) by $0.09. The business had revenue of $50.64 million during the quarter, compared to the consensus estimate of $33.00 million. During the same quarter in the prior year, the company posted ($0.65) earnings per share. On average, equities research analysts expect that FibroGen will post -0.91 earnings per share for the current fiscal year.
Institutional Investors Weigh In On FibroGen
Hedge funds have recently made changes to their positions in the stock. Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of FibroGen in the first quarter valued at about $131,000. Pennant Investors LP bought a new stake in shares of FibroGen in the fourth quarter valued at about $681,000. Acadian Asset Management LLC lifted its stake in FibroGen by 1.4% during the first quarter. Acadian Asset Management LLC now owns 2,503,865 shares of the biopharmaceutical company’s stock worth $5,883,000 after purchasing an additional 34,937 shares during the period. Accel Wealth Management bought a new position in FibroGen during the first quarter worth about $103,000. Finally, Armistice Capital LLC lifted its stake in FibroGen by 23.7% during the fourth quarter. Armistice Capital LLC now owns 9,764,000 shares of the biopharmaceutical company’s stock worth $8,654,000 after purchasing an additional 1,872,000 shares during the period. Institutional investors own 72.71% of the company’s stock.
About FibroGen
FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.
See Also
- Five stocks we like better than FibroGen
- Following Congress Stock Trades
- Can Celsius Stock Rebound? Analysts See 74% Upside Potential
- How to Know Which Cryptocurrency to Buy: A Guide for Investors
- Kroger Stock is a Win-Win for Buy-and-Hold Investors
- Why Invest in High-Yield Dividend Stocks?
- MarketBeat Week in Review – 9/9 – 9/13
Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.